BridgeBio(US:BBIO)2025-10-29 20:02Financial Performance - Total third quarter revenue reached $120.7 million, with $108.1 million from U.S. Attruby net product revenue, $4.3 million from royalty revenue, and $8.3 million in license and services revenue[2]. - Total revenues for the nine months ended September 30, 2025, were $347.9 million, a $131.9 million increase from the prior year, primarily driven by a $216.4 million increase in net product revenue from Attruby[14]. - The company reported net product revenue of $108.1 million for the three months ended September 30, 2025, compared to no revenue in the same period of 2024, and total revenues of $120.7 million for the same quarter[27]. - The net loss attributable to common stockholders for the three months ended September 30, 2025, was $182.7 million, compared to $162.0 million for the same period in 2024[24]. - Net loss for the nine months ended September 30, 2025, was $538.3 million, compared to a net loss of $276.0 million for the same period in 2024[34]. - Cash used in operating activities increased to $389.5 million in 2025 from $325.4 million in 2024[34]. - Cash paid for interest decreased to $43.7 million in 2025 from $78.2 million in 2024[37]. - Cash, cash equivalents, and restricted cash at the end of the period were $645.1 million, up from $407.9 million in 2024[35]. - Net cash provided by financing activities was $361.5 million in 2025, compared to $274.5 million in 2024[35]. Research and Development - The Phase 3 study of BBP-418 showed a 1.8x increase in glycosylated αDG from baseline at 3 months (p<0.0001) and an average reduction in serum CK of 82% at 12 months (p<0.0001) compared to placebo[2]. - The primary endpoint of the CALIBRATE Phase 3 study for encaleret was met, with 76% of participants achieving target calcium levels at Week 24 compared to 4% on conventional therapy (p<0.0001)[11]. - The company plans to file NDAs for both BBP-418 and encaleret with the FDA in the first half of 2026[2]. - The company expects topline results from the PROPEL 3 study of infigratinib in early 2026, with the study fully enrolled[11]. - BridgeBio plans to initiate clinical trials of encaleret in pediatric ADH1 and chronic hypoparathyroidism in 2026[2]. - The company has a robust pipeline with multiple upcoming milestones, including data sharing from the Phase 3 ACCEL 2/3 study in hypochondroplasia in 2026[2]. - The company emphasizes the potential for BBP-418 to become the first approved treatment for LGMD2I/R9[43]. Operating Expenses - For the three months ended September 30, 2025, total operating costs and expenses were $265.9 million, an increase of $71.4 million from $194.5 million in the same period of 2024, primarily driven by a $68.8 million increase in selling, general and administrative expenses[15]. - For the nine months ended September 30, 2025, total operating costs and expenses were $731.7 million, up from $583.0 million in the prior year, reflecting a $179.0 million increase in selling, general and administrative expenses[17]. - Stock-based compensation expenses for the three months ended September 30, 2025, were $35.3 million, an increase from $27.1 million in the same period of 2024[18]. - Total other income (expense), net for the three months ended September 30, 2025, was $(41.3) million, a decrease of $68.8 million compared to $27.5 million in the prior year[20]. Patient and Prescription Data - As of October 25, 2025, there have been 5,259 unique patient prescriptions written by 1,355 unique prescribers, indicating strong month-over-month growth in the treatment naïve patient segment[2]. Cash and Assets - BridgeBio ended the quarter with $645.9 million in cash, cash equivalents, and marketable securities, providing strong capital to advance its pipeline[2]. - Cash, cash equivalents, and marketable securities as of September 30, 2025, totaled $645.9 million, down from $681.1 million at the end of 2024[30]. - The company had total assets of $998.3 million as of September 30, 2025, compared to $919.3 million at the end of 2024[30]. Product Information - Attruby is indicated for the treatment of cardiomyopathy of transthyretin-mediated amyloidosis (ATTR-CM) in adults[39]. - Adverse reactions for Attruby included diarrhea (11.6% vs 7.6% for placebo) and upper abdominal pain (5.5% vs 1.4% for placebo)[40].